Succinate Dehydrogenase-Deficient Renal Cancer Featuring Fructose-1,6-Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report

MICHAL SZYMANSKI, a NATALIA RUSETSKA, b IGA JANCEWICZ, b ALICJA ARMATOWSKA, b MARCIN LIGAJ, c ALICJA CHRZAN, c KINGA HINCZA, d ARTUR KOWALIK, d,e PAWEL MIKA, f, MACIEJ KISIEL, f JAKUB ZOLNIEREK, f, JOANNA KOSIOR, f TOMASZ DEMKOW, a,f JAKUB ZOLNIEREK, a,f JOANNA KOSIOR, g TOMASZ DEMKOW, a

Departments of aUro-oncology, bMolecular and Translational Oncology, and cPathology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; dDepartment of Molecular Diagnostics HolyCross Cancer Center, Kielce, Poland; eDivision of Medical Biology, Institute of Biology Jan Kochanowski University, Kielce, Poland; fRegional Hospital in Biala Podlaska, Biala Podlaska, Poland; gInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

†Contributed equally.

Disclosures of potential conflicts of interest may be found at the end of this article.

ABSTRACT

Succinate dehydrogenase (SDH)-deficient renal cancer is a rare renal cancer subtype recently accepted by the World Health Organization as a unique subtype of renal cell carcinoma (RCC). Here we report a case of a 17-year-old man. The detailed evaluation indicated occurrence of the SDHB-deficient RCC. The genetic testing revealed no germline mutation in SDH genes. Immunohistochemistry showed SDHB deficiency, overexpression of pyruvate kinase M2 and dramatic downregulation of fructose-1,6-bisphosphatase metabolic enzymes, and unaltered levels of phosphorylated AMP-activated protein kinase and mammalian target of rapamycin. Strong upregulation of INI1 and BRG1 and overexpression of BAF180, subunits of SWI/SNF ATP-dependent chromatin remodeling complex, were also found. The identified tumor pathologically did not resemble clear cell renal cell carcinoma (ccRCC), but some metabolic alterations are common for both cancer types. Thus, we postulate that the phenotypical differences between ccRCC and SDHB-deficient RCC may be related to distinct molecular and metabolic alterations.

The Oncologist 2021;26:1–4

Implications for Practice: Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) is a rare renal tumor occurring even in young patients. Until now, in all described and genetically tested cases, mutations and deletions in SDH genes have been found. This article describes SDHB-deficient RCC without any germline mutations in SDH genes. Therefore, genetic analysis for germline mutations in SDH genes in SDH-deficient RCC, especially in young individuals, should be strongly recommended, although as of now it is not obligatory. This knowledge will allow improvement of patient monitoring including both disease recurrence and new cancer appearance.

BACKGROUND

Succinate dehydrogenase (SDH)-deficient renal cell carcinoma (RCC) was originally described in 2004. In 2016 it was accepted by the World Health Organization as a separate rare RCC subtype representing around 0.05%–0.2% of all renal tumors.

Correspondence: Tomasz J. Sarowski, D.Sc., Institute of Biochemistry and Biophysics, Polish Academy of Sciences Pawinskiego 5A, 02-106 Warsaw, Poland. Telephone: 48225925781; e-mail: tsarn@ibb.waw.pl; or Elzbieta Sarowska, D.Sc., Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5 Str. 02-781 Warsaw, Poland. Telephone: 48225462782; e-mail: elzbieta.sarowska@pib-nio.pl  Received November 10, 2019; accepted for publication February 17, 2021. http://dx.doi.org/10.1002/onco.13825

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The Oncologist 2021;26:1–4 www.TheOncologist.com © 2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
RCCs [1]. Around 75% of all patients with SDH-deficient RCC carry a germline mutation in the gene encoding the SDHB subunit of the SDH complex, which is composed of four proteins, SDHA, SDHB, SDHC, and SDHD. Mutations in the SDHA, SDHC, and SDHD genes are less frequent. Until now only 59 SDH-deficient RCC cases have been described [2–6]. Patients’ ages at diagnosis ranged from 14 to 76 years. Only seven cases were reported for patients aged younger than 20 years [2]. Patients harboring SDH mutations have a lifetime risk to develop RCC of around 14% and are also predisposed to develop paragangliomas, pheochromocytomas, and gastrointestinal stromal tumors. Usually, SDH-deficient RCC is diagnosed as a low-grade tumor with a good prognosis. The metastasis rate is approximately 33% [2].

SDH, the succinate dehydrogenase complex, is involved in both the Krebs cycle (tricarboxylic acid cycle) and the electron transport chain. SDH enables conversion of succinate to fumarate [7]. SDH loss leads to overaccumulation of metabolic intermediates, that is, succinate, a signaling molecule in processes involved in inflammation and cancer and that affect chromatin status [8]. Some RCC types, such as clear cell renal cell carcinoma (ccRCC), are characterized by aberrations in the switch/sucrose non fermentable (SWI/SNF) chromatin remodeling complex (CRC), which is involved in the control of gene expression and cancer development via chromatin structure [9].

**CASE PRESENTATION**
A 17-year-old man, otherwise healthy, reported pain on the right side of his abdomen lasting a few weeks. No gastrointestinal stromal tumor, paraganglioma, or pheochromocytoma was reported in his family. On examination all routinely tested parameters were normal. Ultrasonography examination showed a pathological mass in the right kidney.
Computed tomography (CT) of the abdomen and pelvis (Fig. 1A) with contrast material confirmed the presence of a solid mass (diameter 35 mm) at the back-lower pole of the right kidney (Fig. 1B). CT scan of the chest revealed no evidence for metastatic cancer. In April 2017 a partial right nephrectomy was performed. The pathological examination revealed the occurrence of SDH-deficient RCC classified as International Society of Urological Pathology nucleolar grade 2. The standard immunohistochemistry (Fig. 1C) indicated negative SDHB staining in cancer cells (Fig. 1D).

The genetic test for germline mutation in SDH was performed; DNA was isolated from blood samples and examined using Ion Torrent next-generation sequencing (Thermo Fisher Scientific, Waltham, MA). The sequencing for exon panel of VHL, RET, SDHA, SDHB, SDHC, SDHD, SDHAF1, SDHAF2, and MAX was successful with 100% coverage at ×20 coverage depth. No germline mutations or deletions were found. The exons not covered by the panel were additionally sequenced using the Sanger method.

Given the occurrence of metabolic alterations in another RCC (ccRCC) [9], we examined the abundance of fructose-1,6-bisphosphatase (FBP1) (Fig. 1E) and pyruvate kinase M2 (PKM2) (Fig. 1F) proteins in this case. We found nearly complete loss of FBP1 and strong overexpression of PKM2 in cancer cells compared with healthy tissue.

In ccRCC, mutations and aberrations of SWI/SNF CRC occur [9, 10]. Thus, we examined the abundance of the main SWI/SNF CRC subunits (INI1, BRM, BRG1, BAF155, and BAF180; Fig. 2A–E). Whereas for BRM and BAF155 no alterations were observed, BRG1 ATPase, INI1, and BAF180 were overexpressed in SDHB-deficient cancer cells. Subsequently, we tested the abundance of activated AMPK (phosphorylated at Tyr172) and mammalian target of rapamycin (mTOR) kinase, as ccRCC exhibits mTOR hyperactivation and loss of AMPK activity.
No differences in AMPK activation (Fig. 2F) and mTOR abundance (Fig. 2G) were found, further indicating that SDHB-deficient RCC (Fig. 2H) and ccRCC are characterized by different metabolic alterations.

At follow-up with the patient 1 year after surgery, no evidence of disease recurrence was found (Fig. 2I).

**Discussion**

SDHB deficiency is usually caused by either point mutation or deletion in the SDHB gene. Mutations in other SDH genes may also result in SDHB deficiency.

Here we describe, for the first time, the SDHB-deficient RCC without germline point mutations or deletions in any SDH genes. Thus, the existence of SDH mutations seems not to be an obligatory factor for occurrence of this cancer type. This observation is consistent with higher frequency of particular SDHB point mutations in the population than the occurrence of SDHB-deficient cancers [11].

The studied case featured FBP1 loss and PKM2 overexpression, suggesting the metabolic switch to aerobic glycolysis known as the Warburg effect [12]. Observed metabolic disorders partially resembled these in ccRCC (FBP1 loss, tricarboxylic acid impairment); however, SDHB-deficient RCC accumulates succinate, whereas ccRCC accumulates fatty acids.

In contrast to the loss of SWI/SNF CRCs observed in ccRCC, here we found overexpression of BRG1, INI1, and BAF180 subunits. Some SWI/SNF CRC subunits have been reported as tumor suppressors; for example, transient INI1 restoration in ccRCC caused downregulation of metastasis-related genes [9]. Other subunits may act as oncogenes; for example, overexpression of BRM ATPase correlates with increased expression of chemoresistance-related genes in adenoid cystic carcinoma [12]. Thus, we postulate that the differential aberrations in SWI/SNF CRC could be related to different aggressiveness in ccRCC and SDHB-deficient RCCs. Because of overexpression, the protective function of INI1 and BRG1 subunits may be more pronounced in the SDHB-deficient RCC; however, it needs to be confirmed in a larger group of patients. Additionally, in the SDHB-deficient tumor neither overexpression of mTOR nor loss of AMPK activity was found, confirming the different metabolic alterations in ccRCC and SDHB-deficient RCC.

**Conclusion**

SDHB-deficient RCC primary tumor is characterized by metabolic aberrations, including FBP1 loss, PKM2 overexpression, and overaccumulation of some SWI/SNF CRC subunits. Loss of SDHB is not necessarily caused by mutations in SDH genes.

**Acknowledgments**

This study was funded by the National Science Centre (NCN) UMO-2014/13/B/N22/01187 and Polpharma Scientific Foundation 5/XVII/18 for T.J.S.

**Disclosures**

The authors indicated no financial relationships.

**References**

1. Wang G, Rao P. Succinate dehydrogenase-deficient renal cell carcinoma: A short review. Arch Pathol Lab Med 2018;142:1284–1288.

2. Gill AJ, Hes O, Papathomas T et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: A morphologically distinct entity: A clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol 2014;38:1588–1602.

3. Kumar R, Bonert M, Naqvi A et al. SDH-deficient renal cell carcinoma-clinical, pathologic and genetic correlates: A case report. BMC Urol 2018;18:109–114.

4. Iwashita H, Okudela K, Matsumura M et al. Succinate dehydrogenase B-deficient renal cell carcinoma: A case report with novel germline mutation. Pathol Int 2017;67:585–589.

5. McEvoy CR, Koe L, Choong DY et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: Comprehensive genetic profiling and its relation to therapy response. NPJ Precis Oncol 2018;2:9.

6. Gupta S, Swanson A, Chen YB et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC. Hum Pathol 2019;91:114–122.

7. Killian JK, Kim SY, Miettinen M et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov 2013;3:648–657.

8. Mills E, O’Neill LAJ. Succinate: A metabolic signal in inflammation. Trends Cell Biol 2014;24:313–320.

9. Sarnowska E, Szymanski M, Rusetska N et al. Evaluation of the role of downregulation of SNF5/INI1 core subunit of SWI/SNF complex in clear cell renal cell carcinoma development. Am J Cancer Res 2017;7:2275–2289.

10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–49.

11. Ying N, Zbuk KM, Sadler T et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet 2008;83:261–268.

12. Jagielska B, Sarnowska E, Rusetska N et al. Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations. J Cancer Res Clin Oncol 2019;145:201–211.